WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 120206
CAS#: 138844-81-2 (sodium)
Description: Ibandronate sodium is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. It may also be used to treat hypercalcemia (elevated blood calcium levels). Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.
MedKoo Cat#: 120206
Name: Ibandronate sodium
CAS#: 138844-81-2 (sodium)
Chemical Formula: C9H23NO7P2
Exact Mass: 319.09498
Molecular Weight: 319.23
Elemental Analysis: C, 29.76; H, 5.83; N, 3.86; Na, 12.66; O, 30.84; P, 17.06
Related CAS #: 89987-06-4 (free acid) 138844-81-2 (sodium) 155453-10-4 (sodium hemihydrate)
Synonym: Ibandronate sodium. trade names: Boniva in the USA Bondronat in Europe Bonviva in Asia and Bondrova in Pakistan.
IUPAC/Chemical Name: sodium hydrogen(1-hydroxy-3-(methyl(pentyl)amino)-1-phosphonopropyl)phosphonate
InChi Key: LXLBEOAZMZAZND-UHFFFAOYSA-M
InChi Code: InChI=1S/C9H23NO7P2.Na/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);/q;+1/p-1
SMILES Code: CCCCCN(CCC(P(O)(O)=O)(P(O)(O[Na])=O)O)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 319.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Inderjeeth CA, Glendenning P, Ratnagobal S, Inderjeeth DC, Ondhia C. Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. Int J Womens Health. 2014 Dec 17;7:7-17. doi: 10.2147/IJWH.S73944. eCollection 2015. Review. PubMed PMID: 25565901; PubMed Central PMCID: PMC4274146.
2: Shiraishi A. [Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate]. Nihon Yakurigaku Zasshi. 2014 Jun;143(6):302-9. Review. Japanese. PubMed PMID: 24919557.
3: Sittig HB. Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate. Onkologie. 2012;35(6):380-7. doi: 10.1159/000338947. Epub 2012 May 22. Review. PubMed PMID: 22722461.
4: Sewerynek E, Stuss M. [The role of i.v. ibandronate administration in osteoporosis therapy]. Endokrynol Pol. 2011;62 Suppl 2:9-18. Review. Polish. PubMed PMID: 22125017.
5: Lee YH, Song GG. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med. 2011 Sep;26(3):340-7. doi: 10.3904/kjim.2011.26.3.340. Epub 2011 Sep 13. Review. PubMed PMID: 22016595; PubMed Central PMCID: PMC3192207.
6: Sewerynek E, Stuss M. The role of i.v. ibandronate administration in osteoporosis therapy. Endokrynol Pol. 2011 Jan-Feb;62(1):51-60. Review. PubMed PMID: 21365580.
7: Tobinai M. [Ibandronate]. Clin Calcium. 2011 Jan;21(1):79-86. doi: CliCa11017986. Review. Japanese. PubMed PMID: 21187598.
8: Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther. 2010 Jan-Mar;6(1):31-5. doi: 10.4103/0973-1482.63570. Review. PubMed PMID: 20479544.
9: Lewiecki EM, Cooper C, Thompson E, Hartl F, Mehta D, Papapoulos SE. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract. 2010 May;64(6):821-6. doi: 10.1111/j.1742-1241.2010.02335.x. Epub 2010 Mar 11. Review. PubMed PMID: 20337751.
10: Meattini I, Bruni A, Scotti V, Livi L, De Luca Cardillo C, Galardi A, Cipressi S, Biti G. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature. J Chemother. 2010 Feb;22(1):58-62. Review. PubMed PMID: 20227995.
11: Morgan C, Wagstaff J. Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases? Acta Oncol. 2009;48(6):882-9. doi: 10.1080/02841860902874748. Review. PubMed PMID: 19925378.
12: Epstein S, Jeglitsch M, McCloskey E. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Review. PubMed PMID: 19835464.
13: Amling M, Kurth A. Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy. Womens Health (Lond Engl). 2009 Sep;5(5):467-73. doi: 10.2217/whe.09.38. Review. PubMed PMID: 19702445.
14: Rossini M, Viapiana O, Gatti D, Adami S. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clin Ther. 2009 Jul;31(7):1497-510. doi: 10.1016/j.clinthera.2009.07.018. Review. PubMed PMID: 19695399.
15: Lakatos P. [Ibandronate in the treatment of postmenopausal osteoporosis]. Lege Artis Med. 2008 Oct;18(10):657-61. Review. Hungarian. PubMed PMID: 19227607.
16: Miller PD, Ward P, Pfister T, Leigh C, Body JJ. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. Clin Exp Rheumatol. 2008 Nov-Dec;26(6):1125-33. Review. PubMed PMID: 19210886.
17: Frampton JE, Perry CM. Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Drugs. 2008;68(18):2683-707. doi: 10.2165/0003495-200868180-00011. Review. PubMed PMID: 19093707.
18: Emkey RD. Quarterly intravenous ibandronate for postmenopausal osteoporosis. Womens Health (Lond Engl). 2008 May;4(3):219-28. doi: 10.2217/17455057.4.3.219. Review. PubMed PMID: 19072470.
19: Bauss F, BergstrÃ¶m B. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment. Curr Clin Pharmacol. 2008 Jan;3(1):1-10. Review. PubMed PMID: 18690873.
20: Reginster JY, Neuprez A, BruyÃ¨re O. Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):941-51. doi: 10.1517/17425255.4.7.941 . Review. PubMed PMID: 18624681.
Ibandronate sodium inhibits farnesyl diphosphate synthase (IC50 = 20 nM). Ibandronate sodium is also a bone resorption inhibitor. It has been investigated for in vitro anti-tumor effects, such as apoptosis induction, inhibitor of cell growth, inhibition of invasive behavior, and inhibition of angiogenesis and for its in vivo role in various cancers including breast and prostate cancers.